In a closed-door meeting at a Manhattan mansion, executives outlined changes to controversial software that was implicated in two crashes.Aerospace & Defenseread more
Current and former Tesla employees working in the company's open-air "tent" factory say they felt pressure to take shortcuts to hit aggressive Model 3 production goals,...Technologyread more
Minutes from the Reserve Bank of Australia's monetary policy meeting in July showed the central bank was ready to adjust interest rates if required.Asia Marketsread more
President Donald Trump and the RNC are picking up key supporters in the business community who did not back him as a candidate in 2016.2020 Electionsread more
Amazon workers in Minnesota and Germany are striking as Prime Day kicks off, in a stand against working conditions and wage practices. The action in Minnesota represents the...Retailread more
Treasury Secretary Steven Mnuchin is raising red flags ahead of Facebook's proposed cryptocurrency launch.Marketsread more
Epstein is accused of sexually exploiting dozens of underage girls from 2002 through 2005 at his New York and Florida residences. He is a former friend of Presidents Donald...Politicsread more
When you think of Prime Day, you might be thinking about deals on Instant Pots and Amazon Echo devices — not half-off dresses and designer heels. But the market for apparel...Retailread more
David Marcus, the head of Facebook's digital currency project, said the company expects Libra will drive more advertising revenue for the company.Technologyread more
Some White House officials expect the Cabinet secretary, who has known the president for years, to depart as soon as this summer.Politicsread more
"The important thing is that you shouldn't try to hit homeruns this week, because you're much more likely to end up striking out," Jim Cramer says.Mad Money with Jim Cramerread more
Major insurer Cigna — which is engaged in an effort to reduce abuse of prescription painkillers — announced Wednesday that it will effectively stop covering the cost of use of the opioid OxyContin by customers of its employer-based health plans beginning in January.
At the same time, Cigna announced a contract to continue covering a competing oxycodone alternative to OxyContin, which will impose a financial penalty on that drug's maker if too much of the drug ends up being used by the insurer's customers.
Oxycodone is used to treat moderate to severe pain.
Cigna's moves come more than a year after the insurer said it intended to cut opioid use among its customers by 25 percent by 2019.
More than half of those deaths were linked to prescription opioids such as OxyContin. The rest were related to heroin or to fentanyl, a synthetic opioid.
"Our focus is on helping customers get the most value from their medications — this means obtaining effective pain relief while also guarding against opioid misuse," said Jon Maesner, Cigna's chief pharmacy officer on Wednesday.
OxyContin is the only opioid-based prescription painkiller that Cigna is removing in 2018 as "a preferred option" from its formulary, or list of medications that its health plans will pay for.
While Maesner said that Cigna would review individual prescriptions for OxyContin that are deemed "medically necessary" by a physician, the drug essentially is "being removed" from coverage by the insurer.
Cigna said that people who have already started using OxyContin for hospice care or cancer treatments will continue to have that medication covered next year.
Cigna said it has begun notifying customers who currently have OxyContin prescriptions, as well as their doctors, of the decision to stop covering the opioid "so that they have time to discuss treatment options and covered oxycodone clinical alternatives.
Maesner, who would not identify how many Cigna customers currently use OxyContin, said the insurer is "not specifically singling out Oxycontin."
But, he added, "we found a strong sense of commitment" to reducing opioid overuse from Collegium Pharmaceuticals, the maker of the oxycodone alternative that Cigna will continue to cover.
However, a spokesman for Purdue Pharma, the privately held Connecticut company that makes OxyContin, suggested there is little, if any, difference in between the two opioids in how they affect patients.
The spokesman, Robert Josephson, said OxyContin and Xtampza ER, the opioid that Cigna is continuing to cover, are both long-acting oxycodones.
Josephson also noted that both OxyContin and Xtampa ER are formulated in a way to deter abuse.
"We believe that patients should have access to FDA [Food and Drug Administration]-approved products with abuse deterrent properties," Josephson said.
"Unfortunately, Cigna's decision limits the tools prescribers can use to help address the opioid crisis as both products are formulated with properties designed to deter abuse."
Xtampza ER is made by Collegium Pharmaceutical.
Cigna said that under the terms of the contract the insurer signed with Collegium that kicks in Jan. 1, "Collegium is financially accountable if the average daily dosage strengths of Xtampza ER prescribed for Cigna customers exceed a specific threshold."
"If the threshold is exceeded, Collegium will reduce the cost of the medication for many of Cigna's benefit plans," Cigna said.
Purdue Pharma has been sued by a number of states and cities in the past year for alleged deceptive marketing of its opioids.
"I don't know how executives at Purdue sleep at night," State of Washington Attorney General Bob Ferguson said last week as he announced one of those lawsuits accusing the drugmaker of downplaying the addictiveness OxyContin.
Purdue Pharma, which has declined the suits' claims, has noted that its products account for only 2 percent of all opioid prescriptions.
In 2007, the company and three Purdue Pharma executives pleaded guilty to federal criminal charges related to misbranding of OxyContin. Purdue Pharma agreed to pay $600 million in fines and other payments, while the executives agreed to pay $34.5 million in fines.
Cigna in 2016 announced a goal of slashing use of opioids among its customers by 25 percent over the next three years. Cigna said that as part of that initiative it would encourage doctors to prescribe the drugs in lesser quantities and for lesser amounts of time.
Last April, the insurer said opioid use among Cigna customers had already declined by 12 percent.